NASDAQ:MIRO • US60471P1084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MIROMATRIX MEDICAL INC (MIRO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-12 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-04-03 | Piper Sandler | Maintains | Overweight |
| 2022-11-15 | Piper Sandler | Maintains | Overweight |
| 2022-08-31 | Piper Sandler | Initiate | Overweight |
| 2021-07-19 | Craig-Hallum | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50K -80.00% | 30K -40.00% | 950K 3,066.67% | 14.28K -98.50% | 13.77K -3.57% | 13.77K | 24.508M 177,881.12% | 110.19M 349.61% | 440.64M 299.89% | 2.143B 386.34% | 6.479B 202.33% | |
| EBITDA YoY % growth | -10.09M -16.65% | -16.79M -66.40% | -29.25M -74.21% | -27.03M 7.59% | -34.17M -26.42% | -57.12M -67.16% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.26M -14.13% | -16.96M -65.30% | -30.36M -79.01% | -28.623M 5.72% | -36.91M -28.95% | -56.075M -51.92% | -49.228M 12.21% | 36.862M 174.88% | 37.026M 0.44% | 393.41M 962.52% | 1.26B 220.28% | |
| Operating Margin | -20,520.00% | -56,533.33% | -3,195.79% | -200,442.86% | -268,048.15% | -407,225.93% | -200.87% | 33.45% | 8.40% | 18.36% | 19.45% | |
| EPS YoY % growth | N/A | N/A | -1.45 -79.95% | -0.98 32.47% | -0.87 11.46% | -1.10 -26.47% | -1.01 7.91% | 0.67 166.67% | 0.32 -53.03% | 3.33 951.61% | 10.66 220.55% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 35.09% | -0.19 42.82% | -0.21 10.75% | -0.21 12.88% | -0.25 -16.67% | -0.27 -43.24% | -0.23 -9.29% | -0.28 -33.66% | -0.31 -25.31% |
| Revenue Q2Q % growth | 3.57K -99.62% | 3.57K -64.30% | 3.57K -64.30% | 3.57K -64.30% | 3.57K | 3.57K | 3.57K | 3.57K | 3.57K |
| EBITDA Q2Q % growth | -6.222M -2.50% | -7.344M 5.97% | -8.364M -36.89% | -8.364M -44.96% | -10.2M -63.93% | -11.322M -54.17% | -11.424M -36.59% | -16.626M -98.78% | -17.748M -74.00% |
| EBIT Q2Q % growth | -6.792M 5.40% | -7.455M 7.96% | -8.679M -29.73% | -9.444M -42.23% | -11.382M -67.58% | -11.628M -55.97% | -11.73M -35.15% | -16.932M -79.29% | -18.054M -58.62% |
All data in USD
8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.
The consensus EPS estimate for the next earnings of MIROMATRIX MEDICAL INC (MIRO) is -0.21 USD and the consensus revenue estimate is 3.57K USD.
The number of analysts covering MIROMATRIX MEDICAL INC (MIRO) is 8.